Skip to main content

Advertisement

SpringerLink
Log in

18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer

  • Short Communication
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The usefulness of positron emission tomography/computed tomography (PET/CT) using (18F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (18F-FPPRGD2) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study.

Methods

Seven patients with mRCC were enrolled in this prospective study. 18F-FPPRGD2 and 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUVmax) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy.

Results

Sixty lesions in total were detected in this cohort. SUVmax from 18F-FPPRGD2 PET/CT was lower than that from 18F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUVmax and T/B from 18F-FPPRGD2 PET/CT decreased after starting antiangiogenic therapy (SUVmax, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUVmax and T/B were − 29.3 ± 23.6% and − 48.1 ± 28.3%, respectively.

Conclusions

18F-FPPRGD2 PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:804–34.

    Article  Google Scholar 

  2. Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, et al. Glioblastoma multiforme recurrence: an exploratory study of 18F FPPRGD2 PET/CT. Radiology. 2015;277:497–506.

    Article  PubMed  Google Scholar 

  3. Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, et al. Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 2016;43:1047–55.

    Article  PubMed  Google Scholar 

  4. Iagaru A, Mosci C, Shen B, Chin FT, Mittra E, Telli ML, et al. 18F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology. 2014;273:549–59.

    Article  PubMed  Google Scholar 

  5. Withofs N, Signolle N, Somja J, Lovinfosse P, Nzaramba EM, Mievis F, et al. 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology. J Nucl Med. 2015;56:361–4.

    Article  CAS  PubMed  Google Scholar 

  6. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  PubMed  Google Scholar 

  7. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–9.

    Article  PubMed  Google Scholar 

  8. Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:1534–43.

    Article  CAS  PubMed  Google Scholar 

  9. Withofs N, Martinive P, Vanderick J, Bletard N, Scagnol I, Mievis F, et al. [18F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:654–62.

    Article  CAS  PubMed  Google Scholar 

  10. Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol. 2016;27:1685–95.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The study was supported by a grant to Dr. Holly M. Thompson from Alpern Foundation. Alice C. Fan receives funding support from ASCO Conquer Cancer Foundation Career Development Award and is a founder of Molecular Decisions Inc. Andrei Iagaru receives institutional research support from GE Healthcare.

Author information

Author notes

  1. Akira Toriihara and Heying Duan contributed equally to this work.

Authors and Affiliations

  1. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA

    Akira Toriihara, Heying Duan, Sonya Park, Negin Hatami, Lucia Baratto & Andrei Iagaru

  2. Department of Nuclear Medicine, Kaiser Permanente, Santa Clara, CA, USA

    Holly M. Thompson

  3. Division of Oncology, Department of Medicine, Stanford University, 269 Campus Drive, Stanford, CA, 94305, USA

    Alice C. Fan

Authors
  1. Akira Toriihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heying Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Holly M. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sonya Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Negin Hatami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lucia Baratto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alice C. Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrei Iagaru
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Alice C. Fan or Andrei Iagaru.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Conflict of interest

Alice C. Fan receives funding support from ASCO Conquer Cancer Foundation Career Development Award and is a founder of Molecular Decisions Inc.

Andrei Iagaru receives institutional research support from GE Healthcare (unrelated to this study).

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 123 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toriihara, A., Duan, H., Thompson, H.M. et al. 18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer. Eur J Nucl Med Mol Imaging 46, 1518–1523 (2019). https://doi.org/10.1007/s00259-019-04295-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04295-7

Keywords

Search

Navigation